Latest Manufacturing News

EVE Health Group has completed its acquisition of Nextract, raised $1 million to fund manufacturing, and achieved key regulatory and commercial milestones for its pharmaceutical products targeting erectile dysfunction and dysmenorrhea.

Janus Electric Holdings has relaunched on the ASX, securing $8.8 million to accelerate its heavy vehicle electrification strategy, including a key supply agreement with Electrovaya for next-generation lithium-ion batteries.

Ionic Rare Earths advances its rare earths strategy with major UK government funding, Brazilian JV progress, and US expansion talks amid China export controls.

Electro Optic Systems (EOS) has secured its largest-ever order for the Slinger Counter-Drone system, boosting its contract backlog by 25% to $170 million and reporting strong cash flow and a debt-free balance sheet.

Australian Vanadium Limited (AVL) reports strong progress on its integrated vanadium project, moving closer to final feasibility and advancing its utility-scale battery storage system, Project Lumina.

Volt Group reported a 15% decline in Q2 FY25 revenue due to customer order timing delays but secured new Wescone orders pointing to a strong Q3 recovery. Meanwhile, EcoQuip and ATEN projects advanced with promising demonstrations and feasibility studies.

Dotz Nano has partnered with CarbonCapture Inc. to scale its high-performance direct air capture sorbent, while raising AU$1.2 million to fund its DotzEarth project amid ongoing funding timing challenges.

Rhythm Biosciences has successfully validated its ColoSTAT® colorectal cancer test, secured its first strategic partnership for Genetype, and secured $1 million in non-dilutive funding, setting the stage for a transformative FY26.

Carnegie Clean Energy has made significant strides in advancing its wave energy technologies, signing key MOUs and achieving critical milestones in the ACHIEVE Programme during the June 2025 quarter.

Acrux Limited has secured a decade-long licensing agreement with Servacure to commercialise its FDA-approved Dapsone 5% Gel in Saudi Arabia, marking a strategic step in its global expansion.

Matrix Composites & Engineering has landed a new A$10 million subsea buoyancy contract for a Gulf of Mexico project, adding to over A$45 million in awards this financial year and reinforcing its global SURF market presence.

Amplia Therapeutics reports encouraging ACCENT trial results for its FAK inhibitor narmafotinib, including rare complete responses in pancreatic cancer, alongside a $27.5 million capital raise to fund ongoing clinical development.